全文获取类型
收费全文 | 104504篇 |
免费 | 9918篇 |
国内免费 | 5789篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 4544篇 |
妇产科学 | 2282篇 |
基础医学 | 9085篇 |
口腔科学 | 542篇 |
临床医学 | 9627篇 |
内科学 | 25180篇 |
皮肤病学 | 656篇 |
神经病学 | 1938篇 |
特种医学 | 3372篇 |
外国民族医学 | 21篇 |
外科学 | 24605篇 |
综合类 | 15995篇 |
现状与发展 | 31篇 |
一般理论 | 2篇 |
预防医学 | 3383篇 |
眼科学 | 1315篇 |
药学 | 7670篇 |
45篇 | |
中国医学 | 4674篇 |
肿瘤学 | 5123篇 |
出版年
2024年 | 184篇 |
2023年 | 1744篇 |
2022年 | 2283篇 |
2021年 | 3935篇 |
2020年 | 4017篇 |
2019年 | 3910篇 |
2018年 | 3882篇 |
2017年 | 3980篇 |
2016年 | 4394篇 |
2015年 | 3989篇 |
2014年 | 6516篇 |
2013年 | 7127篇 |
2012年 | 5508篇 |
2011年 | 6528篇 |
2010年 | 5337篇 |
2009年 | 5336篇 |
2008年 | 5513篇 |
2007年 | 5723篇 |
2006年 | 5555篇 |
2005年 | 4847篇 |
2004年 | 3972篇 |
2003年 | 3436篇 |
2002年 | 2868篇 |
2001年 | 2513篇 |
2000年 | 2138篇 |
1999年 | 1718篇 |
1998年 | 1570篇 |
1997年 | 1390篇 |
1996年 | 1275篇 |
1995年 | 1068篇 |
1994年 | 1137篇 |
1993年 | 787篇 |
1992年 | 855篇 |
1991年 | 647篇 |
1990年 | 538篇 |
1989年 | 461篇 |
1988年 | 455篇 |
1987年 | 343篇 |
1986年 | 302篇 |
1985年 | 475篇 |
1984年 | 352篇 |
1983年 | 233篇 |
1982年 | 278篇 |
1981年 | 224篇 |
1980年 | 179篇 |
1979年 | 137篇 |
1978年 | 143篇 |
1977年 | 113篇 |
1976年 | 116篇 |
1975年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
目的:探究原发性肝癌患者手术切除术后早期复发影响因素分析。方法:对广州市番禺区中医院2017年2月-2019年2月收治的原发性肝癌患者98例进行回顾性分析,依据各项临床指标分析手术切除术后早期复发的影响因素。结果:原发性肝癌患者经由手术切除后出现复发的可能性较高,同时手术切缘有残留、包膜不完整、肿瘤结节、心理因素、甲胎蛋白、血管侵犯、肝硬化及肿瘤直径等均是影响原发性肝癌手术期后再复发的高危因素。结论:原发性肝癌通常具有术后复发的生物学特性,依据对手术切除术之后早期复发因素的分析,对手术风险与治疗方案进行充分评估,同时要求患者进行定期复查及随访等工作,可对患者手术成功以及并发症的防治等均具有积极意义。 相似文献
52.
53.
Worsening pneumonitis due to a pharmacokinetic drug–drug interaction between everolimus and voriconazole in a renal transplant patient
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
54.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
55.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
56.
57.
《Molecular therapy》2020,28(6):1432-1441
- Download : Download high-res image (155KB)
- Download : Download full-size image
58.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献59.
60.
工作相关肌肉骨骼疾患(WMSDs)是常见的慢性非传染性疾病。WMSDs已成为影响工人健康、降低工人生命质量和造成经济损失的重要因素,可见于多个行业、工种。本文对WMSDs流行现状及人体工效学负荷相关研究进行综述,以期找到职业人群保护的可行方法。 相似文献